176 related articles for article (PubMed ID: 29537684)
1. Cost-effectiveness analysis of salvage therapies in locoregional previously irradiated head and neck cancer.
Kim H; Vargo JA; Beriwal S; Clump DA; Ohr JP; Ferris RL; Heron DE; Huq MS; Smith KJ
Head Neck; 2018 Aug; 40(8):1743-1751. PubMed ID: 29537684
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck.
Leung HW; Lang HC; Wang SY; Leung JH; Chan AL
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):489-495. PubMed ID: 33729079
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant stereotactic body radiotherapy±cetuximab following salvage surgery in previously irradiated head and neck cancer.
Vargo JA; Kubicek GJ; Ferris RL; Duvvuri U; Johnson JT; Ohr J; Clump DA; Burton S; Heron DE
Laryngoscope; 2014 Jul; 124(7):1579-84. PubMed ID: 24123056
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Murphy JD; Chang DT; Abelson J; Daly ME; Yeung HN; Nelson LM; Koong AC
Cancer; 2012 Feb; 118(4):1119-29. PubMed ID: 21773972
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of single fraction of stereotactic body radiation therapy compared with single fraction of external beam radiation therapy for palliation of vertebral bone metastases.
Kim H; Rajagopalan MS; Beriwal S; Huq MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):556-63. PubMed ID: 25680599
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
7. Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck.
van der Linden N; van Gils CW; Pescott CP; Buter J; Vergeer MR; Groot CA
Eur Arch Otorhinolaryngol; 2015 Aug; 272(8):2007-16. PubMed ID: 24943191
[TBL] [Abstract][Full Text] [Related]
8. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
[TBL] [Abstract][Full Text] [Related]
9. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck.
Vargo JA; Ferris RL; Ohr J; Clump DA; Davis KS; Duvvuri U; Kim S; Johnson JT; Bauman JE; Gibson MK; Branstetter BF; Heron DE
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):480-8. PubMed ID: 25680594
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of SBRT versus IMRT: an emerging initial radiation treatment option for organ-confined prostate cancer.
Hodges JC; Lotan Y; Boike TP; Benton R; Barrier A; Timmerman RD
Am J Manag Care; 2012 May; 18(5):e186-93. PubMed ID: 22694113
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
Kim H; Vargo JA; Ling DC; Beriwal S; Smith KJ
Am J Clin Oncol; 2019 Nov; 42(11):837-844. PubMed ID: 31644441
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation.
Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M
Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.
Pollom EL; Lee K; Durkee BY; Grade M; Mokhtari DA; Wahl DR; Feng M; Kothary N; Koong AC; Owens DK; Goldhaber-Fiebert J; Chang DT
Radiology; 2017 May; 283(2):460-468. PubMed ID: 28045603
[TBL] [Abstract][Full Text] [Related]
15. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study.
Comet B; Kramar A; Faivre-Pierret M; Dewas S; Coche-Dequeant B; Degardin M; Lefebvre JL; Lacornerie T; Lartigau EF
Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):203-9. PubMed ID: 22331006
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Compared With Radiofrequency Ablation for Inoperable Colorectal Liver Metastases.
Kim H; Gill B; Beriwal S; Huq MS; Roberts MS; Smith KJ
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1175-83. PubMed ID: 27130789
[TBL] [Abstract][Full Text] [Related]
17. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
[TBL] [Abstract][Full Text] [Related]
19. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Leung HW; Chan AL; Muo CH
Clin Ther; 2016 May; 38(5):1174-83. PubMed ID: 27033672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]